Clinical Pharmacology

Question 0

Which polymorphism is associated with increased toxicities (neutropenia, and probably diarrhea) due to irinotecan?

Answer 0

UGT1A1*28

Question 1

Which condition can cause severe toxicities for patients receiving 5-FU?

Answer 1

Dihydropyrimidine dehydrogenase (DPD) deficiency. This is the first of 3 enzymes in the fluoropyrimidine metabolic pathway.

Question 2

Vinorelbine is extensively metabolized in the liver via which enzyme?

Answer 2

CYP3A

Question 3

Compared to once-every-3-week regimen, weekly paclitaxel for metastatic breast cancer has ___ RR and time to progression.

Answer 3

Better

Question 4

Patient with a history of Gilbert’s syndrome receiving FOLFIRINOX developed febrile neutropenia after 1 cycle. What changes should be made for subsequent cycles?

Answer 4

Dose-reduce irinotecan

Question 5

What is a pharmacodynamic endpoint?

Answer 5

The relationship between an administered dose of a drug and a change in a biologic target.

Question 6

What drug converts methotrexate into inactive metabolites that can be eliminated from the body via nonrenal pathways?

Answer 6

Glucarpidase

Question 7

A patient develops grade 2 neuropathy on paclitaxel. Switch to nab-paclitaxel?

Answer 7

No! Worse neuropathy with nab-paclitaxel.